MYH9 and kidney disorder: With reference to methodological issues inherent in these cross-sectional studies and the geographical variations in the prevalence of HbAS, additional examination of SCT has been suggested in well-characterised, geographically diverse populations with advanced kidney disease.5 It may also be interesting to examine the interaction of SCT with other recently identified genetic risks for ESRD in black individuals, such as apolipoprotein 1 (APOL1) and non-muscle myosin heavy-chain 9 (MYH9).5